Novo Nordisk’s Reckoning as Price Wars Redefine the Economics of Obesity Drugs
Novo Nordisk’s warning of “unprecedented” pricing pressure marks a turning point not just for the company, but for the broader obesity drug market that until recently appeared insulated from the usual forces of pharmaceutical competition. After years of near-exponential growth driven by soaring demand for Wegovy and related therapies, the Danish drugmaker is confronting a…









